Trials / Completed
CompletedNCT03055650
iLux Treatment for Meibomian Gland Dysfunction (MGD)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Tear Film Innovations, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess changes in meibomian gland function and evaporative dry eye symptoms after treatment with the iLux medical device.
Detailed description
Alcon Research, LLC, acquired TearFilm Innovations, Inc., in December 2018. This study was designed and conducted by TearFilm Innovations, Inc. The study results were collected, analyzed, and provided by TearFilm Innovations, Inc., to Alcon Research, LLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | iLux 2020 System | Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands |
Timeline
- Start date
- 2015-12-07
- Primary completion
- 2016-02-18
- Completion
- 2016-02-18
- First posted
- 2017-02-16
- Last updated
- 2020-11-12
- Results posted
- 2020-11-12
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03055650. Inclusion in this directory is not an endorsement.